logo-loader
RNS
MedPal AI plc

New Health and Mounjaro

RNS Number : 0217Z
Medpal AI PLC
15 October 2026
 

15 October 2026

MedPal AI plc

("MedPal", the "Company" or the "Group")

New Health enters the top 30 UK Mounjaro providers in three months

Ranked 29th by Eli Lilly, with over 42,500 customers and 2.1% GLP-1 market share

 

Eli Lilly, the exclusive supplier of GLP-1 Mounjaro, has confirmed that New Health has risen from 3,048th to 29th place in its supplier list (by volume supplied). This has taken approximately three months since the Company's initial marketing campaign began.

Novo Nordisk, in written evidence to the House of Commons Health and Social Care Committee in August 2025, estimated that approximately 2 million people in the UK were using GLP-1 medicines for weight management, over 90 per cent. of them privately. New Health now has over 42,500 customers, representing approximately 2.1 per cent. of this market, up from more than 33,000 as at 30 September 2026

On the basis of Eli Lilly's ranking, the Directors consider New Health to be among the fastest growing GLP-1 providers in the UK and the Group remains on track to open its expanded GLP-1 line at Sarus Court by the end of October 2026, taking capacity to 14,000 orders a day.

 

Jason Drummond, Founder and Chief Executive Officer, commented:

"From 3,048th to 29th in three months. Eli Lilly's own ranking confirms the scale of what New Health has built since July. We now have more than 42,500 customers, representing approximately two per cent. of the UK's GLP-1 users.

"Two weeks ago we said repeat orders would grow as customers reached their first reorder date. They now make up over 30 per cent. of New Health revenue, up from 22 per cent. in September, with no acquisition cost attached. Our ambition is to be a top three UK GLP-1 provider. The expanded line at Sarus Court opens this month with capacity for 14,000 orders a day. This is what the Health OS was built for, and it is only the beginning."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

 

Enquiries

MedPal AI plc - Jason Drummond, Chief Executive Officer: via Square1 Consulting

Cairn Financial Advisers LLP (Nomad) - Louise O'Driscoll / Jo Turner: +44 (0) 20 7213 0880

Merlin Partners LLP (formerly Oak Securities) - +44 (0) 20 7839 3500

Clear Capital Markets Limited - Bob Roberts: +44 (0) 20 3869 6080

Square1 Consulting - David Bick: +44 (0) 20 7929 5599 / +44 (0) 7831 381201

 

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a vertically integrated, AI-native digital health and pharmacy group. The Group operates NHS Distance Selling Pharmacy hubs at Sarus Court, Runcorn and Swaffham, New Health (new.co.uk), a dedicated GLP-1 weight management clinic, a B2B care home pharmacy supply business, eMARx, the Group's electronic medication administration record software for care homes, and Juno, an agentic AI health companion built on Anthropic's Claude. MedPal's ambition is to build the UK's leading Health OS: a single platform connecting prescribing, dispensing, delivery, administration and AI-driven patient support. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements, which are based on the Company's current expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These statements, including statements regarding the Group's market position, the opening of additional capacity and trading in October 2026, are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Third party market estimates referred to in this announcement have not been independently verified by the Company. No statement in this announcement is intended to be a profit forecast. The Company undertakes no obligation to update any forward-looking statements except as required by law or the AIM Rules for Companies.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRDGBDGGDBDGLS
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read